Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: Pfizer | Clear Filter
Summary:The post asserts the critical importance of drug companies justifying the success of their various Covid drugs amidst public disagreement and controversy involving the CDC. It states that extraordinary positive data from companies like Pfizer has been shown to the author but is being withheld from the public and the CDC, demanding immediate disclosure to resolve the ongoing debate regarding the drugs' success and the efficacy of Operation Warp Speed.
Sentiment:Demanding Transparency
Key Claims:
- Drug companies must justify the success of their Covid drugs.
- There is significant public disagreement and controversy regarding the success of Covid drugs, impacting the CDC.
- Extraordinary positive data from Pfizer and other companies regarding Covid drugs exists but is not being shown to the public.
- Drug companies are not adequately addressing public questions about their Covid work.
- There is an immediate demand for drug companies to show their data on Covid drug success to the CDC and the public to resolve the issue.
- The success of Operation Warp Speed needs to be confirmed, and if not, the reasons for its failure must be explained.
Potential Market Impact (S&P 500):4/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:3/10
Summary:A letter from The White House, dated July 31, 2025, to Pfizer CEO Albert Bourla, outlines an Executive Order signed on May 12, 2025, aimed at ending high drug prices in the United States by mandating Most-Favored-Nation pricing for all drugs for American patients, and warns of consequences if drug manufacturers do not comply within 60 days.
Sentiment:Authoritative Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to implement Most-Favored-Nation (MFN) drug pricing for American patients.
- American drug prices are up to three times higher than in other developed nations due to 'global freeloading'.
- The Administration demands Pfizer and all drug manufacturers extend MFN pricing to Medicaid patients for existing drugs.
- The Administration demands Pfizer and all drug manufacturers guarantee MFN pricing for newly-launched drugs for all payers.
- The Administration demands increased revenues from abroad be repatriated to lower US drug prices.
- The Administration demands participation in direct purchasing models at MFN pricing.
- Non-compliance will result in the deployment of 'every tool in our arsenal' to protect American families.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:5/10
« Previous
Page 1 of 1
Next »